MMP-13 inhibitors (AstraZeneca)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMMP-13 inhibitors (AstraZeneca)
Drug Alias Namemetalloprotease-13 (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 13 inhibitors
TargetsMatrix metalloproteinase 13
Therapy Area/IndicationsOsteoarthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsOsteoarthritis

Other Information

ATC CodeN/A
Related LinksN/A